Insider · CIK 0001579824
Charles M Baum
director
Files at PSTX (Poseida Therapeutics, Inc.), PMVP (PMV Pharmaceuticals, Inc.), ACRV (Acrivon Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 13, 2025 | ACRV Acrivon Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +20,275 | $0.00 | $0 | 20,275 | Jun 17, 2025 |
| Jun 5, 2025 | PMVP PMV Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +33,500 | $0.00 | $0 | 33,500 | Jun 9, 2025 |
| Jan 8, 2025 | PSTX Poseida Therapeutics, Inc. | UTender of shares Common Stock | -78,600 | - | - | 0 | Jan 8, 2025 |
| Jan 8, 2025 | PSTX Poseida Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -57,000 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | PSTX Poseida Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -27,350 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | PSTX Poseida Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -27,350 | $0.00 | $0 | 0 | Jan 8, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.